StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a report released on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on APTO. Cantor Fitzgerald upped their price target on Aptose Biosciences from $6.00 […]
StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) in a research report report published on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock. A number of other equities research analysts have also recently commented on APTO. Royal Bank of Canada lowered their target price on […]
Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) had its target price boosted by Oppenheimer from $9.00 to $50.00 in a report released on Monday morning, The Fly reports. APTO has been the topic of several other research reports. Royal Bank of Canada reduced their target price on shares of Aptose Biosciences from $75.00 to $40.00 […]
Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) had its price target lowered by Royal Bank of Canada from $75.00 to $40.00 in a research report report published on Wednesday, The Fly reports. Several other research analysts have also weighed in on the stock. StockNews.com began coverage on shares of Aptose Biosciences in a research note […]
Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) had its price target trimmed by Piper Sandler from $45.00 to $37.00 in a research report report published on Wednesday, The Fly reports. A number of other research analysts also recently weighed in on the stock. Royal Bank of Canada reaffirmed an outperform rating and issued a $75.00 […]